YOLFTbeta
Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc.

CDT · NASDAQ · Healthcare / Biotechnology

0.4004USD-0.04 (-9.66%)

Price History

Full chart

Market Stats

Previous Close0.4432
Open0.4347
Day Range0.38 – 0.4478
52-Week Range0.0786 – 1,778.00
Volume776.75K
Market Cap1.10M
P/E (TTM)0.00
Forward P/E0.00
EPS-2,814.22
Dividend Yield0.00%
Beta1.45
50-Day Avg2.05
200-Day Avg113.20

About

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Joanne M. Holland
  • Employees4
  • Headquarters4581 Tamiami Trail North, Naples, FL, United States, 34103, USA
  • Websitehttps://www.cdtequity.com

Leadership

  • Dr. Joanne M. HollandChief Scientific Officer · b. 1975
  • Dr. David Joszef TapolczayHead of Strategy & Licensing · b. 1959

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000922.22M2.72B
Growth (%)----+194.42%
Cost of Revenue---457.00K1.68B
Gross Profit----457.00K1.03B
Gross Margin----0.05%37.98%
Operating Expense---14.96M1.07B
Operating Income-3.17M-3.16M-5.26M-15.42M-36.76M
Operating Margin----1.67%-1.35%
EBITDA-3.66M-4.89M3.05M-15.84M-36.48M
EBITDA Margin----1.72%-1.34%
Net Income-3.66M-4.89M-535.00K-17.80M-39.22M
Net Income Margin----1.93%-1.44%
R&D283.00K111.00K90.00K3.38M5.05M
R&D as % of Total Revenue---0.37%0.19%
Interest Expense-0211.00K1.51M319.00K
Interest Expense % of Total Revenue---0.16%0.01%

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets213.13K5.00K7.22M4.19M3.54B
Total Liabilities192.51K10.09M7.68M10.99M2.28B
Total Equity20.62K-10.09M-457.00K-6.79M1.26B
Cash48.55K345.78K4.23M554.00K389.89M
Total Debt177.06K2.01M985.00K7.46M1.29B
Net Debt128.50K2.01M-3.24M6.90M895.78M

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.15M-2.27M-7.72M-9.68M-15.55M
Investing Cash Flow48.55K-183.00K725.00K-43.00K-808.00K
Financing Cash Flow1.90M2.45M10.93M6.07M17.42M
Capital Expenditure50051.00K2.40M
Free Cash Flow-2.15M-2.27M-7.72M-9.73M-17.96M
Dividends Paid---8.20M7.97M
FCF to OCF100.00%100.00%100.00%100.53%115.45%
Dividend Paid to FCF----84.20%-44.36%

Earnings

Report DateMay 18, 2022Aug 11, 2022Nov 7, 2022Mar 28, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Mar 28, 2025May 15, 2025Aug 14, 2025Nov 12, 2025Dec 31, 2025Jun 25, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate0.000.000.000.00---------------
EPS Actual-0.02-0.010.010.0397628.07-165034.67-9208.77-45824.50-145104.50-218668.69-222396.70-2.15-1.32-5.46-13.16-2314.41-99.99-8.71-
Surprise-------------------
Timing-------------After-hoursAfter-hours----

Key Statistics & Ratios

Market Cap1.10M
Enterprise Value2.28M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.02
EPS-2,814.22
Book Value163.36
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-22.83M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-69.68%
Return on Assets-23.44%
Shares Outstanding13.69M
Shares Float343.92K
Beta1.45
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
0.09%
Insiders
43.21%
Retail / Other
56.70%

Top Institutional Holders

  • Financial Management Professionals Inc
    10.01K0.16%
  • Tower Research Capital LLC
    1100.00%
  • Virtu Financial LLC
    00.00%
  • Morgan Stanley - Brokerage Accounts
    20.00%
  • Apollon Wealth Management, LLC
    00.00%
  • SBI Securities Co Ltd
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    1.48K0.10%
  • Fidelity Nasdaq Composite Index
    1970.01%

Stock Splits

  • Nov 6, 20261:20
  • Jul 20, 20261:10
  • Mar 27, 20261:25
  • Oct 13, 20251:8
  • May 20, 20251:15
  • Jan 27, 20251:100